• 1
    Robertson DL, Sharp PM, McCutchan FE, Hahn BH. Recombination in HIV-1. Nature 1995; 374: 124126.
  • 2
    Leitner T, Korber B, Daniels M, Calef C, Foley B. HIV-1 Subtype and Circulating Recombinant Form (CRF) Reference Sequences, 2005. Los Alamos National Laboratory, Los Alamos, NM 87545. Available at (accessed March 2010).
  • 3
    Taylor BS, Hammer SM. The challenge of HIV-1 subtype diversity. New Engl J Med 2008; 12: 15901602.
  • 4
    Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006; 20: W13W23.
  • 5
    Lukashov VV, Kuiken CL, Vlahov D, Coutinho RA, Goudsmit J. Evidence for HIV type 1 strains of U.S. intravenous drug users as founders of AIDS epidemic among intravenous drug users in northern Europe. AIDS Res Hum Retroviruses 1996; 12: 11791183.
  • 6
    Sonnerborg A, Durdevic S, Giesecke J, Sällberg M. Dynamics of the HIV-1 subtype distribution in the Swedish HIV-1 epidemic during the period 1980 to 1993. AIDS Res Hum Retroviruses 1997; 13: 343345.
  • 7
    Balotta C, Facchi G, Violin M et al. ICONA study group. Increasing prevalence of non-clade B HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences. J Acquir Immune Defic Syndr 2001; 27: 499505.
  • 8
    Chaix ML, Descamps D, Harzic M et al. Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS 2003; 17: 26352643.
  • 9
    Snoeck J, Van Laethem K, Hermans P et al. Rising prevalence of HIV-1 non-B subtypes in Belgium: 1983–2001. J Acquir Immune Defic Syndr 2004; 35: 279285.
  • 10
    Lospitao E, Alvarez A, Soriano V, Holguín A. HIV-1 subtypes in Spain: a retrospective analysis from 1995 to 2003. HIV Med 2005; 6: 313320.
  • 11
    Gifford RJ, De Oliveira T, Rambaut A et al. Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1. J Virol 2007; 81: 1305013056.
  • 12
    Palma AC, Araújo F, Duque V, Borges F, Paixão MT, Camacho R. Portuguese SPREAD network. Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal. Infect Genet Evol 2007; 7: 391398.
  • 13
    Yerly S, Von Wyl V, Ledergerber B et al. Swiss HIV cohort study. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 2007; 21: 22232229.
  • 14
    Masquelier B, Bhaskaran K, Pillay D et al. CASCADE collaboration. Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr 2005; 40: 505511.
  • 15
    Wensing AM, Vijver DA, Angarano G et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192: 958966.
  • 16
    Wensing AMJ, Vercauteren J, Vijver DA et al. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 2008; 22: 625635.
  • 17
    Thomson MM, Pérez-Alvarez L, Nájera R. Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis 2002; 2: 461471.
  • 18
    Notiziario COA Marzo 2009. Available at (accessed March 2010).
  • 19
    Lemey P, Derdelinckx I, Rambaut A et al. Molecular footprint of drug-selective pressure in a human immunodeficiency virus transmission chain. J Virol 2005; 79: 1198111989.
  • 20
    Hué S, Gifford RJ, Dunn D, Fernhill E, Pillay D. UK collaborative group on HIV drug resistance. Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naïve individuals. J Virol 2009; 83: 26452654.
  • 21
    Zazzi M, Riccio ML, Venturi G et al. Long-read direct infrared sequencing of crude PCR products for prediction of resistance to HIV-1 reverse transcriptase and protease inhibitors. Mol Biotechnol 1998; 10: 18.
  • 22
    Peduzzi C, Pierotti P, Venturi G et al. Performance of an in-house genotypic antiretroviral resistance assay in patients pretreated with multiple human immunodeficiency virus type 1 protease and reverse transcriptase inhibitors. J Clin Virol 2002; 25: 5762.
  • 23
    Oelrichs RB, Workman C, Laukkanen T, McCutchan FE, Deacon NJ. A novel subtype A/G/J recombinant full-length HIV type 1 genome from Burkina Faso. AIDS Res Hum Retroviruses 1998; 14: 14951500.
  • 24
    Nasioulas G, Paraskevis D, Magiorkinis E, Theodoridou M, Hatzakis A. Molecular analysis of the full-length genome of HIV type 1 subtype I: evidence of A/G/I recombination. AIDS Res Hum Retroviruses 1999; 15: 745758.
  • 25
    Monno L, Brindicci G, Lo Caputo S et al. HIV-1 subtypes and circulating recombinant forms (CRFs) from HIV-infected patients residing in two regions of central and southern Italy. J Med Virol 2005; 75: 483490.
  • 26
    Baldanti F, Paolucci S, Ravasi G et al. Changes in circulation of B and non-B HIV strains: spotlight on a reference centre for infectious diseases in Northern Italy. J Med Virol 2008; 80: 947952.
  • 27
    Thomson MM, Nájera R. Molecular epidemiology of HIV-1 variants in the global AIDS pandemic: an update. AIDS Rev 2005; 7: 210224.
  • 28
    Op De Coul E, Van Den Burg R, Asjö B et al. Genetic evidence of multiple transmissions of HIV type 1 subtype F within Romania from adult blood donors to children. AIDS Res Hum Retroviruses 2000; 16: 327336.
  • 29
    Thomson M, Sierra M, Tanuri A et al. Analysis of near full-length genome sequences of HIV type 1 BF intersubtype recombinant viruses from Brazil reveals their independent origins and their lack of relationship to CRF12_BF. AIDS Res Hum Retroviruses 2004; 20: 11261133.
  • 30
    Razzolini F, Vicenti I, Saladini F et al. Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy. AIDS Res Hum Retroviruses 2007; 23: 558563.
  • 31
    Holguín A, López M, Molinero M, Soriano V. Performance of three commercial viral load assays, versant human immunodeficiency virus type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, testing HIV-1 non-B subtypes and recombinant variants. J Clin Microbiol 2008; 46: 29182923.
  • 32
    Lobritz MA, Marozsan AJ, Troyer RM, Arts EJ. Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity. J Virol 2007; 81: 82588269.
  • 33
    Huang W, Eshleman SH, Toma J et al. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol 2007; 81: 78857893.
  • 34
    Martinez-Cajas JL, Pai NP, Klein MB, Wainberg MA. Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996–2008). J Int AIDS Soc 2009; 12: 1–11.
  • 35
    Ariën KK, Abraha A, Quiñones-Mateu ME, Kestens L, Vanham G, Arts EJ. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol 2005; 79: 89798990.
  • 36
    Keller M, Lu Y, Lalonde RG, Klein MB. Impact of HIV-1 viral subtype on CD4+T-cell decline and clinical outcomes in antiretroviral naive patients receiving universal healthcare. AIDS 2009; 23: 731737.
  • 37
    Eshleman SH, Guay LA, Mwatha A et al. Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV network for prevention trials 012. J Acquir Immune Defic Syndr 2005; 39: 593597.